ENHANCED IN VIVO EFFICACY AND SAFETY OF COMBINATION TEMOZOLOMIDE AND BROMODOMAIN INHIBITOR THERAPY FOR GLIOMAS USING A TARGETED DUAL DRUG-LOADING STEALTH LIPOSOMAL CARRIER
Publication
, Conference
Lam, FC; Morton, SW; Wyckoff, J; Maffa, A; Balkanska-Sinclair, E; Floyd, SR; Yaffe, MB; Hammond, PT
Published in: NEURO-ONCOLOGY
November 1, 2017
Duke Scholars
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 1, 2017
Volume
19
Start / End Page
273 / 273
Location
San Francisco, CA
Publisher
OXFORD UNIV PRESS INC
Conference Name
Joint Conference of 22nd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology / Conference of the Society-for-CNS-Interstitial-Delivery-of-the-Therapeutics (SCIDOT) on Therapeutic Delivery to the CNS
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lam, F. C., Morton, S. W., Wyckoff, J., Maffa, A., Balkanska-Sinclair, E., Floyd, S. R., … Hammond, P. T. (2017). ENHANCED IN VIVO EFFICACY AND SAFETY OF COMBINATION TEMOZOLOMIDE AND BROMODOMAIN INHIBITOR THERAPY FOR GLIOMAS USING A TARGETED DUAL DRUG-LOADING STEALTH LIPOSOMAL CARRIER. In NEURO-ONCOLOGY (Vol. 19, pp. 273–273). San Francisco, CA: OXFORD UNIV PRESS INC.
Lam, Fred C., Stephen W. Morton, Jeffrey Wyckoff, Amanda Maffa, Elena Balkanska-Sinclair, Scott R. Floyd, Michael B. Yaffe, and Paula T. Hammond. “ENHANCED IN VIVO EFFICACY AND SAFETY OF COMBINATION TEMOZOLOMIDE AND BROMODOMAIN INHIBITOR THERAPY FOR GLIOMAS USING A TARGETED DUAL DRUG-LOADING STEALTH LIPOSOMAL CARRIER.” In NEURO-ONCOLOGY, 19:273–273. OXFORD UNIV PRESS INC, 2017.
Lam FC, Morton SW, Wyckoff J, Maffa A, Balkanska-Sinclair E, Floyd SR, et al. ENHANCED IN VIVO EFFICACY AND SAFETY OF COMBINATION TEMOZOLOMIDE AND BROMODOMAIN INHIBITOR THERAPY FOR GLIOMAS USING A TARGETED DUAL DRUG-LOADING STEALTH LIPOSOMAL CARRIER. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2017. p. 273–273.
Lam, Fred C., et al. “ENHANCED IN VIVO EFFICACY AND SAFETY OF COMBINATION TEMOZOLOMIDE AND BROMODOMAIN INHIBITOR THERAPY FOR GLIOMAS USING A TARGETED DUAL DRUG-LOADING STEALTH LIPOSOMAL CARRIER.” NEURO-ONCOLOGY, vol. 19, OXFORD UNIV PRESS INC, 2017, pp. 273–273.
Lam FC, Morton SW, Wyckoff J, Maffa A, Balkanska-Sinclair E, Floyd SR, Yaffe MB, Hammond PT. ENHANCED IN VIVO EFFICACY AND SAFETY OF COMBINATION TEMOZOLOMIDE AND BROMODOMAIN INHIBITOR THERAPY FOR GLIOMAS USING A TARGETED DUAL DRUG-LOADING STEALTH LIPOSOMAL CARRIER. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2017. p. 273–273.
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 1, 2017
Volume
19
Start / End Page
273 / 273
Location
San Francisco, CA
Publisher
OXFORD UNIV PRESS INC
Conference Name
Joint Conference of 22nd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology / Conference of the Society-for-CNS-Interstitial-Delivery-of-the-Therapeutics (SCIDOT) on Therapeutic Delivery to the CNS
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences